Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccine
Polypeptide-based cancer vaccine's organization is optimized for immunogenicity
May 18th, 2006
Scientists have optimized the organization of a polypeptide-based candidate cancer vaccine composed of cryptic tumor peptides to enhance immunogenicity. According to researchers in France, "Polyspecific tumor vaccination should offer broad control of tumor cells and reduce the risk of emergence of immune escape variants. We evaluated the capacity of a polypeptide composed of optimized cryptic peptides derived from three different universal tumor antigens (TERT988Y , HER-2/neu402Y and MAGE-A248V9 ) to induce a polyspecific CD8 cell response both in vivo in HHD mice and in vitro in humans." "A mixture of TERT988Y,...
Source: Biotech Business Week (2006-05-18)
|
